Akebia Therapeutics (STU:AX9) Cyclically Adjusted Revenue per Share: €2.06 (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
45 GF Score
Price €1.22
GF Value €1.11
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Cyclically Adjusted Revenue per Share?

Akebia Therapeutics STU:AX9 +2.73% 45 Cyclically Adjusted Revenue per Share is €2.06 as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 45/100 and a GF Value™ of €1.11 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €0.173. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Akebia Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -4.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Akebia Therapeutics was -5.50% per year. The lowest was -5.50% per year. And the median was -5.50% per year.

As of today (2026-07-09), Akebia Therapeutics's current stock price is €1.221. Akebia Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.06. Akebia Therapeutics's Cyclically Adjusted PS Ratio of today is 0.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Akebia Therapeutics was 1.58. The lowest was 0.09. And the median was 0.53.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Akebia Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.221/2.06
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Akebia Therapeutics was 1.58. The lowest was 0.09. And the median was 0.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Akebia Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Akebia Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Cyclically Adjusted Revenue per Share Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.28 2.50 2.44 2.00

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 2.13 2.03 2.00 2.06

STU:AX9 vs TKNO, ORGO, SIGA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted PS Ratio falls into.


STU:AX9
45GF Score
Akebia Therapeutics Inc STU:AX9
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.173/330.2130*330.2130
=0.173

Current CPI (Mar. 2026) = 330.2130.

Akebia Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.038 241.432 0.052
201703 0.503 243.801 0.681
201706 0.622 244.955 0.838
201709 0.738 246.819 0.987
201712 1.615 246.524 2.163
201803 0.766 249.554 1.014
201806 0.734 251.989 0.962
201809 0.799 252.439 1.045
201812 0.757 251.233 0.995
201903 0.549 254.202 0.713
201906 0.754 256.143 0.972
201909 0.703 256.759 0.904
201912 0.524 256.974 0.673
202003 0.624 258.115 0.798
202006 0.585 257.797 0.749
202009 0.355 260.280 0.450
202012 0.317 260.474 0.402
202103 0.286 264.877 0.357
202106 0.272 271.696 0.331
202109 0.238 274.310 0.287
202112 0.292 278.802 0.346
202203 0.312 287.504 0.358
202206 0.628 296.311 0.700
202209 0.268 296.808 0.298
202212 0.286 296.797 0.318
202303 0.202 301.836 0.221
202306 0.279 305.109 0.302
202309 0.209 307.789 0.224
202312 0.271 306.746 0.292
202403 0.146 312.332 0.154
202406 0.193 314.175 0.203
202409 0.160 315.301 0.168
202412 0.203 315.605 0.212
202503 0.220 319.799 0.227
202506 0.200 322.561 0.205
202509 0.182 324.800 0.185
202512 0.185 324.054 0.189
202603 0.173 330.213 0.173

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.06 mean?
Akebia Therapeutics (STU:AX9) has a Cyclically Adjusted Revenue per Share of €2.06 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Cyclically Adjusted Revenue per Share too high?
Akebia Therapeutics' current Cyclically Adjusted Revenue per Share is €2.06. Overall, Akebia Therapeutics has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cyclically Adjusted Revenue per Share compare to TKNO and ORGO?
Akebia Therapeutics' Cyclically Adjusted Revenue per Share of €2.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Cyclically Adjusted Revenue per Share is €2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.22 — trading 10% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.06. Akebia Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Cyclically Adjusted Revenue per Share is €2.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.22 is trading 10% above its estimated GF Value™ of €1.11. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Cyclically Adjusted Revenue per Share: €2.06
  • GF Value™: €1.11 vs. price of €1.22 (10% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
45GF Score

Get the complete analysis for STU:AX9

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price
€1.11
GF Value